{{Rsnum
|rsid=10789082
|Gene=CYP2J2
|Chromosome=1
|position=59892297
|Orientation=minus
|GMAF=0.1827
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 6.2 | 36.3 | 57.5
| HCB | 5.8 | 40.1 | 54.0
| JPT | 2.7 | 45.1 | 52.2
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 14.0 | 86.0
| CHB | 5.8 | 40.1 | 54.0
| CHD | 7.3 | 42.2 | 50.5
| GIH | 13.9 | 46.5 | 39.6
| LWK | 0.0 | 2.7 | 97.3
| MEX | 6.9 | 39.7 | 53.4
| MKK | 0.0 | 5.1 | 94.9
| TSI | 2.9 | 41.2 | 55.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10789082
|Name_s=
|Gene_s=CYP2J2
|Feature=
|Evidence=PubMed ID:18496133
|Annotation=The G allele of this SNP is associated with increased stroke risk relative to the A allele in white patients, but not in a mixed-race cohort. This SNP showed no association with nonfatal myocardial infarction risk.
|Drugs=
|Drug Classes=
|Diseases=Myocardial Infarction
|Curation Level=Curated
|PharmGKB Accession ID=PA161795935
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10789082
|overall_frequency_n=23
|overall_frequency_d=126
|overall_frequency=0.18254
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}